But when it finally came, the company was ready with two major drugs, Skyreezy and Renvoke. It worked. This week, Avy reported earnings that beat analyst estimates and raised its 2026 outlook. Even if you aren't familiar with the name Abby, you've probably seen some of their commercials. >> There's nothing like clearer skin and better movement. >> This week, the company delivered a solid earnings beat driven by its immunology portfolio of drugs that sent the stock up, recovering from recent losses. Yet, inv ...